NIH → Trial → Commercial · leading-indicator intelligence
See the biotech pipeline move before it's priced.
Every public-company catalyst starts years upstream — as an NIH grant, then a clinical-trial registration, then a phase advance. The market reads these as three unrelated databases. We join them on a time axis and surface the upstream event the moment it lands, with the predicted downstream event and a typical lead-time.
⚠ Research/informational signals from public data (NIH · ClinicalTrials.gov · SEC EDGAR). Not investment advice. Full scope →
1
NIH RePORTER grant
Federal funding lands ~1–3 yr before first-in-human. PI, org, $ amount, mechanism.
2
ClinicalTrials.gov
Grant-funded science enters the clinic. Phase, sponsor, primary-completion date.
3
SEC 8-K / commercial
For public sponsors, phase advances trigger material disclosures (Reg FD).
Three leading signals we surface
- Grant → Trial transition. NIH-funded research that just entered the clinic — the earliest commercialization signal.
- Trial → Filing window. A public sponsor's trial near phase advance or primary completion — a high-probability SEC/PR window.
- Area heat. Grant + trial co-velocity by mechanism (GLP-1, CAR-T, ADC…) — directional BD/M&A pressure.